These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 8059023)

  • 1. Effect of hemodialysis and recombinant human erythropoietin on determinants of blood viscosity.
    Shand BI; Buttimore AL; Lynn KL; Bailey RR; Robson RA
    Ren Fail; 1994; 16(3):407-13. PubMed ID: 8059023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete correction of renal anemia by recombinant human erythropoietin.
    Ludat K; Paulitschke M; Riedel E; Hampl H
    Clin Nephrol; 2000 Feb; 53(1 Suppl):S42-9. PubMed ID: 10746805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood rheology in hemodialysis patients treated with recombinant human erythropoietin.
    Brunner R; Pollok M; Heidel M; Müller R; Degenhardt S; Baldamus CA
    Contrib Nephrol; 1989; 76():306-12; discussion 312-4. PubMed ID: 2582784
    [No Abstract]   [Full Text] [Related]  

  • 4. [Erythropoietin, blood viscosity and hypertension in chronic kidney failure].
    Schaefer RM; Heidland A
    Dtsch Med Wochenschr; 1989 Jun; 114(26):1046-9. PubMed ID: 2661190
    [No Abstract]   [Full Text] [Related]  

  • 5. rHuEPO hyporesponsiveness and related high dosages are associated with hyperviscosity in maintenance hemodialysis patients.
    Erkmen Uyar M; Toprak SK; Saglam H; Tutal E; Bay M; Ilhan O; Bal Z; Sezer S
    ScientificWorldJournal; 2013; 2013():792698. PubMed ID: 24198729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemorheology and fistula function in home hemodialysis patients following erythropoietin treatment: a prospective placebo-controlled study.
    Shand BI; Buttimore AL; Hurrell MA; Wells JE; Inkster JA; Bailey RR; Robson RA; Lynn KL
    Nephron; 1993; 64(1):53-7. PubMed ID: 7880205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of recombinant human erythropoietin (rHuEpo) on the hemostatic system in chronic hemodialysis patients.
    Huraib S; al-Momen AK; Gader AM; Mitwalli A; Sulimani F; Abu-Aisha H
    Clin Nephrol; 1991 Nov; 36(5):252-7. PubMed ID: 1752076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of recombinant human erythropoietin therapy on plasma endothelin-1 levels during hemodialysis.
    Stefanidis I; Mertens PR; Wurth P; Bach R; Makropoulos W; Mann H; Heintz B
    Int J Artif Organs; 2001 Jun; 24(6):367-73. PubMed ID: 11482502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rheology in whole blood and in red blood cells under recombinant human erythropoietin therapy.
    Lerche D; Schmidt R; Zoellner K; Meier W; Paulitschke M; Distler B; Klinkmann H
    Contrib Nephrol; 1989; 76():299-303; discussion 304-5. PubMed ID: 2684529
    [No Abstract]   [Full Text] [Related]  

  • 10. Erythropoietin treatment does not compromise cardiovascular function in chronic renal failure.
    Haedersdal C; Mehlsen J; Stenver D; Nielsen B; Jeppesen L; Winther K
    Angiology; 1994 Mar; 45(3):231-4. PubMed ID: 8129205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of erythropoietin on the dialysis prescription.
    Van Wyck DB
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):71-5. PubMed ID: 1928083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is erythropoietin a survival factor for red blood cells?
    Polenakovic M; Sikole A
    J Am Soc Nephrol; 1996 Aug; 7(8):1178-82. PubMed ID: 8866410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood rheology and hypertension in hemodialysis patients treated with erythropoietin.
    Schaefer RM; Leschke M; Strauer BE; Heidland A
    Am J Nephrol; 1988; 8(6):449-53. PubMed ID: 3218658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients.
    Carlini R; Obialo CI; Rothstein M
    Am J Hypertens; 1993 Feb; 6(2):103-7. PubMed ID: 8471228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of hypertension induced by erythropoietin in patients on hemodialysis.
    Yamakado M; Umezu M; Nagano M; Tagawa H
    Clin Invest Med; 1991 Dec; 14(6):623-9. PubMed ID: 1794212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Echocardiographic findings in hemodialysis patients treated with recombinant human erythropoietin: proposal for a hematocrit most beneficial to hemodynamics.
    Tagawa H; Nagano M; Saito H; Umezu M; Yamakado M
    Clin Nephrol; 1991 Jan; 35(1):35-8. PubMed ID: 2007294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of erythropoietin in human immunodeficiency virus-infected end-stage renal disease patients treated by maintenance hemodialysis.
    Shrivastava D; Rao TK; Sinert R; Khurana E; Lundin AP; Friedman EA
    Am J Kidney Dis; 1995 Jun; 25(6):904-9. PubMed ID: 7771487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral hemodynamics, blood viscosity, and the renin-angiotensin system in hemodialysis patients under therapy with recombinant human erythropoietin.
    Steffen HM; Brunner R; Müller R; Degenhardt S; Pollok M; Lang R; Baldamus CA
    Contrib Nephrol; 1989; 76():292-8. PubMed ID: 2582783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of blood rheology in the pathogenesis of hypertension of hemodialysis patients treated for renal anemia with recombinant human erythropoietin.
    Baldamus CA; Steffen AM; Brunner R; Pollok M
    Contrib Nephrol; 1990; 82():79-85. PubMed ID: 2093531
    [No Abstract]   [Full Text] [Related]  

  • 20. Iron balance following recombinant human erythropoietin therapy for anemia associated with chronic renal failure.
    Hotta T; Ogawa H; Saito A; Ito A
    Int J Hematol; 1991 Jun; 54(3):195-200. PubMed ID: 1747454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.